Journal
/
/
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
JoVE Journal
Cancer Research
This content is Free Access.
JoVE Journal Cancer Research
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
DOI:

08:52 min

November 22, 2021

, , ,

Chapters

  • 00:04Introduction
  • 01:05Generating Single-Cell Suspension
  • 02:38Cell Seeding
  • 04:39Drug Treatment
  • 05:37Readout by Luminescence-Based Survival Assay
  • 06:52Results: The Analysis of Treatment Response of EGFR-Mutant NSCLC Organoid Model to Osimertinib
  • 08:18Conclusion

Summary

Automatic Translation

This protocol describes a standardized evaluation of drug sensitivities to targeted signaling inhibitors in NSCLC patient-derived organoid models.

Related Videos

Read Article